A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer
Primary Sponsor
Victorian Comprehensive Cancer Centre (VCCC)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Accrual Target
32
Final Accrual
32
Closing Date of Accrual
22 November 2022
Trial Chairperson
Dr Steven David, Peter MacCallum Cancer Centre, VIC
Related Post
24 September, 2025
Prostate Cancer Month: Focus on the TROG Genitourinary Working Party
To mark Prostate Cancer Month in September, we asked
24 September, 2025
TROG members and staff celebrate World Radiotherapy Awareness Day
LATEST NEWS: 24 September 2025 TROG Cancer Research staff